Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of kinsenoside in preparation of medicine for preventing and/or treating pulmonary fibrosis

A technique for clematis and pulmonary fibrosis, which is applied in the field of medicine and can solve problems such as lack of compatibility

Active Publication Date: 2021-06-01
GUANGZHOU SHENGPU INVESTMENT MANAGEMENT
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the differences in the etiology, drug regimen and mechanism of different organ fibrosis, there is no obvious compatibility between the drugs for different organ fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of kinsenoside in preparation of medicine for preventing and/or treating pulmonary fibrosis
  • Application of kinsenoside in preparation of medicine for preventing and/or treating pulmonary fibrosis
  • Application of kinsenoside in preparation of medicine for preventing and/or treating pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0076] Example 1 Auroglutinin inhibits the proliferation of lung fibroblasts

[0077] 1. Experimental method

[0078] Lung fibroblasts were purchased from Fenghui Biocell Company.

[0079] (1) Cell culture

[0080] Lung fibroblasts were cultured in high-glucose DMEM medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and glucose concentration 4.5g / L, and the cells were placed at 37°C with 5% CO 2 Incubator, replace the cell culture medium every 2 days. When the cell density was 80%-90%, the cells were digested with trypsin and resuspended for passage.

[0081] (2) Administration

[0082] After observing that the cells were growing well, the cells were digested and resuspended, and fibroblasts were seeded on a black 96-well plate at a density of 3000 cells per well. Add 10ng / mL TGF-β to each well 24h after cell inoculation 1 , to establish a cellular lung fibrosis model, and continue to culture for 24 hours.

[0083] Administration group: After the ...

Embodiment 2

[0096] Example 2 Anti-pulmonary fibrosis experiment of auroside

[0097] 1. Experimental method

[0098] (1) SPF grade Wistar rats were randomly divided into 5 groups according to body weight, 30 rats in each group. They were sham operation group, model group, high-dose auroglutinin group (480mg / (kg·d)), middle-dose group (240mg / (kg·d)) and low-dose group (120mg / (kg·d)).

[0099] (2) Model preparation

[0100] After the experimental animals were purchased, they were reared routinely and adapted to the environment for 7 days. During the experiment, the animals were anesthetized by intraperitoneal injection of 3 mL / kg of 10% chloral hydrate, made to lie supine and fixed on the mouse board, and the hair on the neck was clipped. The skin was routinely disinfected, and a mid-neck incision about 0.5-1 cm in length was made under aseptic operation. Peel off the exposed trachea layer by layer, and then raise the head of the mouse board so that it forms an angle of 30-35° with the ...

Embodiment 3

[0109] Embodiment 3 auroglucoside acute toxicity test

[0110] 1. Experimental method

[0111] The acute toxicity maximum tolerated dose method was used for the test. Set up blank group and auroglutinin (1.4g / mL) group, a total of 2 groups, select 30 SPF-level ICR mice qualified for quarantine, half male and half female, and divide them into random groups according to sex and body weight, with 15 mice in each group. Only fasting for more than 12h before administration, the blank group did not administer, and the drug group was treated with 0.5mL / 10g during the test. 体重 Perform one-time gavage administration. On the day of administration, especially within 0-4 hours after administration, closely observe and record the poisoning manifestations and characteristics, occurrence and recovery time of toxic reactions, and death of animals in each group. Then observe twice a day, that is, once in the morning and once in the afternoon, and observe continuously for 14 days. Before th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of kinsenoside in preparation of a medicine for preventing and / or treating pulmonary fibrosis. Through creative exploration, it is found that the kinsenoside and the derivative thereof have a good treatment effect on pulmonary fibrosis, no adverse reaction exists, and animal pulmonary fibrosis induced by bleomycin hydrochloride can be relieved. The invention provides a new choice for the medicine for treating pulmonary fibrosis, also provides a natural and novel medicine source for treating pulmonary fibrosis diseases, and is efficient, safe and free of toxic and side effects.

Description

technical field [0001] The invention belongs to the technical field of medicine. More specifically, it relates to the application of auroside in the preparation of drugs for preventing and / or treating pulmonary fibrosis. Background technique [0002] Fibrosis can occur in a variety of organs. The main pathological changes are the increase of fibrous connective tissue and the reduction of parenchymal cells in organ tissues. Continuous progress can lead to organ structural damage, functional decline, and even failure, which seriously threaten human health and life. As long as any reason can cause tissue cell damage, it can lead to tissue cell degeneration, necrosis, and inflammatory response. If the damage is small, normal parenchymal cells around the damaged cells will undergo hyperplasia and repair, and this repair can completely restore normal structure and function. However, if the damage is large or repeated damage exceeds the regeneration capacity of the parenchymal cel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7048A61K9/08A61K9/20A61K9/48A61K9/12A61P11/00A23L33/105
CPCA61K31/7048A61K9/0095A61K9/2059A61K9/4866A61K9/0078A61P11/00A23L33/105A23V2002/00A23V2200/314A23V2250/21Y02A50/30
Inventor 付军
Owner GUANGZHOU SHENGPU INVESTMENT MANAGEMENT